For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Neuracle Science Co., Ltd.

USPTO Granted Patents = 18

EPO Patents = 3

Trademarks = 1

Forward Citations = 68

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

Bongcheol Kim (11 out of 11 patents)

Jae Young Seong (9 out of 10 patents)

Dong Sik Kim (9 out of 19 patents)

4. Eun Bee Cho (6 out of 7 patents)

5. Jong Ik Hwang (5 out of 8 patents)

6. Jae-Keun Lee (5 out of 14 patents)

7. Soon-gu Kwon (5 out of 5 patents)

8. Junho Chung (4 out of 19 patents)

9. Junyeong Jin (4 out of 6 patents)

10. Woong Sun (3 out of 5 patents)

11. Won-Ki Kim (3 out of 4 patents)

12. Juwon Shim (3 out of 3 patents)

13. Tae Young Yune (2 out of 4 patents)

14. Jong-Ik Hwang (2 out of 3 patents)

15. Dong-Hoon Kim (2 out of 42 patents)

18 patents: Sort by Forward Citations

1. 12459995 - Use of anti-FAM19A5 antibodies (2025-11-04),

2. 12435130 - Pharmaceutical use of FAM19A5 involved in regulating gliogenesis (2025-10-07),

3. 12247070 - Use of anti-FAM19A5 antibodies for treating atherosclerosis (2025-03-11),

4. 12215338 - Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies (2025-02-04),

5. 12202889 - Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof (2025-01-21),

6. 12077579 - Use of anti-FAM19A5 antibodies for treating fibrosis (2024-09-03),

7. 12072339 - Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment and diagnosis of mood disorders (2024-08-27),

8. 11970532 - Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof (2024-04-30),

9. 11746149 - Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma (2023-09-05),

10. 11739141 - Pharmaceutical use of FAM19A5 involved in regulating gliogenesis (2023-08-29),

11. 11634484 - Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain (2023-04-25),

12. 11618783 - Anti-FAM19A5 antibodies and uses thereof (2023-04-04),

13. 11560425 - Use of anti-FAM19A5 antibodies for treating cancers (2023-01-24),

14. 11332521 - Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof (2022-05-17),

15. 11248023 - Agonist of spexin-based galanin type 2 receptor and use thereof (2022-02-15),

Neuracle Science Co., Ltd. is a leading biotechnology company specializing in innovative solutions for neurodegenerative diseases. Our team of experts is dedicated to developing cutting-edge therapies and diagnostics for conditions such as Alzheimer's and Parkinson's. We are committed to advancing research and improving the quality of life for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

18 Patents

#210 in Seoul

#653 in South Korea

#33,182 in the World

Seoul, South Korea

Neuracle Science Co., Ltd.

Forward Citations = 68

29 inventors:

Bongcheol Kim (11 out of 11 patents)

Jae Young Seong (9 out of 10 patents)

Dong Sik Kim (9 out of 19 patents)

4. Eun Bee Cho (6 out of 7 patents)

5. Jong Ik Hwang (5 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…